New Radioisotope for Cancer Therapy: A new Collaboration to produce copper-67

SASKATOON – Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies.  This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers. Iotron Medical, a spin-out business … Read more

Storied Nuclear Manufacturer, Niagara Energy Products, joins the CNIC

TORONTO – August 24, 2021 – Niagara Energy Products (NEP), a leader in the field of manufacturing radiation shielded containment vessels for isotopes and nuclear contaminated waste, has joined the Canadian Nuclear Isotope Council (CNIC). NEP has a long and storied history in Canada, with three large manufacturing plants in Ontario, providing high-quality jobs in … Read more

New partnership advances medical isotope technology

McMaster University and Promation have signed a Memorandum of Understanding (MoU) to work together to bring a new medical isotope technology developed at McMaster to the marketplace. At the center of this collaboration is a new technology for producing lutetium-177 (Lu-177), an increasingly sought-after medical isotope. Clinical trials have shown that Lu-177-based drugs have tremendous … Read more

CNIC signs historic MOU to collaborate on the 11th International Conference on Isotopes

TORONTO – May 12 , 2021  –The Canadian Nuclear Isotope Council (CNIC)  and the Local Organizing Committee of the 11th International Conference on Isotopes (11ICI) have entered into a Memorandum of Understanding to co-promote and support the conference’s success in 2022. The 11ICI will be  hosted by Sylvia Fedoruk Canadian Centre for Nuclear Innovation in … Read more

BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific

(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company. Developed for the treatment of patients with hepatocellular carcinoma (HCC), TheraSphere treatment is comprised of millions … Read more

Event: Welcome to the CARI Program and Overcoming Commercialization Challenges in the Canadian Isotope Sector, June 23 2021

Welcome to the CARI Program and Overcoming Commercialization Challenges in the Canadian Isotope Sector Wednesday June 23, 11:00 a.m. – 12:00 p.m. CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) working to bring respective resources together to advance an area of tremendous therapeutic and commercial potential … Read more

Event: Innovation, Automation and the Digital Transformation of the Canadian Isotope Sector, May 12 2021

Innovation, Automation and the Digital Transformation of the Canadian Isotope Sector Wednesday May 12, 11:00 a.m. – 12:00 p.m. This event will explore the interdisciplinary partnerships in Canada’s domestic isotope supply chain that are enabling new and innovative patient treatments and increasing the efficiency, ease, and safety of the isotope production, packaging and delivery processes. … Read more

New report shines spotlight on Canadian isotope excellence

Medical isotope ecosystem directory details tremendous capabilities of Canada’s isotope industry.   Today, the Organization of Canadian Nuclear Industries (OCNI) and the Canadian Nuclear Isotope Council (CNIC) released the Canadian Medical Isotope Ecosystem Directory. The directory demonstrates the capabilities of the Canadian isotope sector companies and their leading international expertise as well as highlights the … Read more